Fig. 4
Antitumor effects of cytokine-armed oncolytic HSV-1 in 4T1 mammary tumor model. A Schematic of BALB/c mice with subcutaneous 4T1 tumors treated with oncolytic virus. When tumor sizes reached ~ 100 mm3 (designated as Day 1), the mice were intratumorally injected 1 × 107 PFU oncolytic HSV-1 or the same volume of PBS at days 1, 3, 5, 7 (red arrowheads). The tumor growth was monitored with caliper measurement every three days. B Kaplan–Meier survival curve of tumor bearing mice treated with oncolytic virus (n = 8 mice). The statistical differences between groups were determined using two-tailed log rank (Mantel-Cox) test. *P < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. C Tumor growth curves for all treatment groups in the 4T1 tumor model. Data presented as the means ± SEM (n = 8). The statistical differences between groups were determined by two-way ANOVA with multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. D Tumor volume of treated mice on day 24. Data presented as the means ± SEM. Statistical significance was calculated by one-way ANOVA followed by Bonferroni’s multiple comparisons test. ****p < 0.0001